Semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes, according to new research. Semaglutide is primarily prescribed for adults with type 2 diabetes but is also approved for chronic weight management in adults with obesity or overweight and have at least one other health issue. In the trial, patients treated with semaglutide lost an average of 9.4% of their body weight and experienced improvements in other risk factors for cardiovascular disease. Results from the ‘SELECT — Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes’ trial were presented today during a late-breaking science session at the American Heart Association’s Scientific Sessions 2023 and simultaneously published in the New England Journal of Medicine.
